Coherus Biosciences | CHRS - Net Income


Coherus Biosciences reported $-37.64M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 1.82B 486M Mar/2026
Baxter International USD -15M 1.11B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Fujifilm JPY 84.24B 11.58B Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Merck USD -4.24B 7.2B Mar/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Pacira USD 2.92M 1.28M Mar/2026
Perrigo USD -398.6M 1.02B Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026
Zoetis USD 601M 2M Mar/2026